Our study from the perspective of U.S. payers, aimed to assess the cost-effectiveness of osimertinib vs. placebo among the stage IB to IIIA, EGFR-mutated, completely resected NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.